OT
OTLK.US OUTLOOK THERAPEUTICS INC
- Market cap
- USD 96.4M
- P/E
- -
- P/B
- 38.42x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is OTLK.US undervalued?
Graham numberThe Graham number of OUTLOOK THERAPEUTICS INC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OUTLOOK THERAPEUTICS INC fundamental analysis
No fundamental analysis for OUTLOOK THERAPEUTICS INC yet.
OUTLOOK THERAPEUTICS INC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Ce…
Full company profileOUTLOOK THERAPEUTICS INC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OUTLOOK THERAPEUTICS INC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.98M | 3.81M | 3.09M | 8.15M | 5.85M | 0.00 | 0.00 | 0.00 | 170K | 1.41M | -1.43M |
| Gross Profit | 2.95M | 3.79M | 3.07M | -15.7M | -554K | -262K | -205K | -44.2K | -114K | 657K | -1.69M |
| Operating Income | -51.3M | -35.9M | -29.6M | -36.3M | -35.0M | -51.7M | -63.1M | -53.1M | -71.7M | -67.1M | -51.1M |
| EBITDA | -49.0M | -30.0M | -26.8M | -31.1M | -34.4M | -52.0M | -64.4M | -56.4M | -72.1M | -63.6M | -63.6M |
| Net Income | -53.3M | -38.8M | -30.1M | -34.5M | -35.2M | -53.2M | -66.1M | -59.0M | -75.4M | -62.4M | -63.8M |
| EPS | -495 | -259 | -85 | -38 | -9.71 | -6.96 | -6.23 | -4.72 | -4.06 | -2.45 | -0.47 |
| Balance Sheet | |||||||||||
| Total Assets | 23.7M | 20.7M | 22.3M | 17.1M | 19.7M | 22.8M | 28.5M | 32.3M | 28.8M | 18.6M | 26.2M |
| Total Liabilities | 28.9M | 51.5M | 43.1M | 27.9M | 16.9M | 18.2M | 19.8M | 46.7M | 102M | 50.8M | 36.6M |
| Shareholders' Equity | -5.20M | -30.7M | -20.8M | -10.8M | 2.83M | 4.61M | 8.74M | -14.4M | -73.1M | -32.2M | -10.4M |
| Cash & Short-term Investments | 2.35M | 3.19M | 1.72M | 8.02M | 12.5M | 14.5M | 17.4M | 23.4M | 14.9M | 8.08M | 11.2M |
| Total Debt | 8.73M | 18.4M | 21.9M | 14.9M | 8.80M | 11.9M | 11.0M | 35.6M | 29.7M | 30.2M | 18.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -45.5M | -15.5M | -33.0M | -32.3M | -31.8M | -54.3M | -56.7M | -43.0M | -68.8M | -51.8M | -59.7M |
| Capital Expenditure | 1.10M | 292K | 2.78M | 437K | 3.00 | 0.00 | 0.00 | 2.00 | 0.00 | 3.00 | 0.00 |
| Free Cash Flow | -46.6M | -15.8M | -35.8M | -32.7M | -31.8M | -54.3M | -56.7M | -43.0M | -68.8M | -51.8M | -59.7M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -1,247.0% | -1,154.0% | -756.0% | - | - | - | - |
| ROA | -224.8% | -187.4% | -135.0% | -201.5% | -178.6% | -233.1% | -231.5% | -182.6% | -261.5% | -335.9% | -243.6% |
| Net Profit Margin | -1,788.7% | -1,019.1% | -974.5% | -423.8% | -602.0% | - | - | - | -44,301.0% | -4,416.2% | - |
| Debt to Equity | - | - | - | - | 3.11x | 2.58x | 1.25x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OUTLOOK THERAPEUTICS INC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 166B | 45,795 | - |
| 2019 | USD 625B | 687,109 | - |
| 2018 | USD 1.89T | 5,329,962 | - |
| 2017 | USD 17.0B | 113,037 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Mar 14, 2024.
Who owns OUTLOOK THERAPEUTICS INC
- Insiders 13.95%
- Institutions 29.87%
- Public & others 56.18%
- Shares outstanding 243M
- Free float 177M
Top funds holding OTLK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Albion Enterprise VCT Ord | 9.35M | 3.84% | 0.00% | Mar 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.93M | 2.85% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 783K | 0.32% | +45.26% | Sep 2026 |
| Fidelity Total Market Index | 281K | 0.12% | +42.49% | Sep 2026 |
| Fidelity Series Total Market Index | 268K | 0.11% | +67.78% | Sep 2026 |
| Vanguard Balanced Index Inv | 116K | 0.05% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 46.1K | 0.02% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 41.1K | 0.02% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 2.56K | 0.00% | 0.00% | Sep 2026 |
| Knights of Columbus U.S. All Cap Idx I | 961.00 | 0.00% | +59.37% | Sep 2026 |
Top institutions holding OTLK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 4.38M | 1.80% | +122.50% | Jun 2026 |
| Perceptive Advisors LLC | 3.14M | 1.29% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.99M | 0.82% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.67M | 0.69% | +249.46% | Jun 2026 |
| Jane Street Group LLC | 1.43M | 0.59% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.25M | 0.51% | +106.40% | Jun 2026 |
| Renaissance Technologies Corp | 1.12M | 0.46% | 0.00% | Sep 2026 |
| Susquehanna International Group, LLP | 968K | 0.40% | +622.08% | Jun 2026 |
| HRT FINANCIAL LLC | 785K | 0.32% | +1,058.38% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 662K | 0.27% | +274.82% | Jun 2026 |
| GILPIN WEALTH MANAGEMENT, LLC | 555K | 0.23% | -7.53% | Jun 2026 |
| State Street Corp | 540K | 0.22% | +230.96% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 450K | 0.18% | 0.00% | Jun 2026 |
| Sanctuary Advisors, LLC | 345K | 0.14% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 246K | 0.10% | +116.73% | Jun 2026 |
| Northern Trust Corp | 238K | 0.10% | +252.52% | Jun 2026 |
| SIMPLEX TRADING, LLC | 205K | 0.08% | +54.53% | Jun 2026 |
| LPL Financial Corp | 185K | 0.08% | +449.98% | Jun 2026 |
| UBS Group AG | 152K | 0.06% | +14.39% | Jun 2026 |
| Deutsche Bank AG | 131K | 0.05% | 0.00% | Jun 2026 |
OUTLOOK THERAPEUTICS INC company profile
- Company name
- OUTLOOK THERAPEUTICS INC
- Ticker
- OTLK.US
- Exchange
- USA Stocks
- Listed since
- May 13, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- September
- Address
- 111 S. Wood Avenue, Iselin, NJ, United States, 08830
- Phone
- 609 619 3990
- Website
- outlooktherapeutics.com
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OUTLOOK THERAPEUTICS INC management
7- Mr. Robert Charles JahrPresident, CEO & Director · born 1973
- Mr. Kevin LundquistCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1968
- Mr. Joel PrieveSenior Vice President of Licensing and M&A
- Dr. Surendra Sharma M.D.Senior Vice President of Medical Affairs
- Dr. Jennifer M. Kissner Ph.D.Senior Vice President of Clinical Development & Regulatory Affairs
- Mr. Jedd ComiskeySenior VP - Head of Europe
- Mr. Greg DiPasqualeChief Commercial Officer